You are here

Management of Targeted Therapies: skin toxicities of innovative treatments

By Vincent Sibaud, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris

34 - Vincent Sibaud ANG

Vincent Sibaud stresses the importance of supportive onco-dermatology and regular dermatological monitoring of patients receiving targeted therapies. Most of the receptors that are inhibited in targeted therapy (e.g. EGFR) are physiologically expressed in the skin; therefore, stopping tumour growth frequently leads to a dysregulation of skin homeostasis. Dermatologic toxicities include, for example, hyperkeratotic lesions, fissures and xerosis, vitiligoid and aphtous lesions as well as toxic erythema.

 

Vincent Sibaud, Institut Claudius Regaud, Toulouse, France

Search this site

Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

NEW! Free access to the digital version of a new publication in Cancer Supportive Care


Cancer cachexia: mechanisms and progress in treatment

Authors: Egidio Del Fabbro, Kenneth Fearon, Florian Strasser

This book was supported by an educational grant from Helsinn Healthcare SA.

Featured videos

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo

Share